GLP-1 receptor agonists reduce MACE (HR 0.69) and all-cause mortality (HR 0.67) in Type 2 DiabetesGLP-1 medications show promise for heart health in diabetes

American journal of cardiovascular drugs : drugs, devices, and other interventions Published September 2, 2026 Study authors: Batista Pedro Gomes, Dos Santos Silva Railla Raquel Albino, Montenegro Marcela Vasconcelos, Malik Mu… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that GLP-1 receptor agonists are associated with lower MACE and mortality, though results are exploratory.

This meta-analysis evaluated the clinical impact of GLP-1 receptor agonists in a large cohort of 37,393 patients diagnosed with Type 2 Diabetes and myocardial infarction-defined populations. The study aimed to synthesize evidence regarding cardiovascular outcomes and mortality in this specific patient population. The study design and setting were not reported, but the large sample size provides a broad overview of the effects of GLP-1 receptor agonists on cardiovascular health in patients with comorbid diabetes and heart disease.

The intervention consisted of GLP-1 receptor agonists. The specific dosing protocols, individual drug names, and the details of the comparator groups were not reported. This lack of specific comparator data limits the ability to determine the relative magnitude of effect against standard-of-care treatments or placebo in this specific analysis.

Regarding primary and secondary outcomes, the meta-analysis reported a significant reduction in all-cause mortality, with a reported HR of 0.67 (95% CI 0.49-0.90; P = 0.0085). Additionally, a significant reduction in MACE was observed with an HR of 0.69 (95% CI 0.56-0.84; P = 0.0002). The analysis also found a significant reduction in heart failure (HF) or hospitalization for heart failure, reported as HR 0.78 (95% CI 0.62-0.98; P = 0.0306).

Several other cardiovascular outcomes did not reach statistical significance. Cardiovascular death showed an HR of 0.85 (95% CI 0.67-1.06; P = 0.15). Recurrent myocardial infarction (MI) showed an HR of 0.82 (95% CI 0.62-1.09; P = 0.1753). Stroke also did not reach statistical significance with an HR of 0.91 (95% CI 0.68-1.22; P = 0.5237).

Safety and tolerability data, including specific adverse event rates, serious adverse events, or discontinuation rates, were not reported. Consequently, the tolerability profile of the intervention in this specific population cannot be quantified from this source.

These results contribute to the existing body of evidence regarding GLP-1 receptor agonists in metabolic and cardiovascular health. While the meta-analysis shows significant reductions in MACE and all-cause mortality, the results are characterized as exploratory. This is due to substantial heterogeneity in the included studies and the presence of wide prediction intervals (PIs). Furthermore, the application of HKSJ adjustment led to an attenuation of statistical significance, which must be considered when interpreting the strength of the findings.

Clinically, these results suggest that GLP-1 receptor agonists may offer significant protection against MACE and all-cause mortality in patients with Type 2 Diabetes and myocardial infarction. However, the high heterogeneity and the specific methodological limitations mean these findings should be interpreted with caution. Practitioners should note that while the association is clear, the exploratory nature of the data means it does not yet provide a definitive basis for changing standard protocols without considering the broader evidence base. Questions remain regarding the specific impact of different GLP-1 agonists and the long-term durability of these outcomes in diverse patient subgroups.

How this fits prior evidence

How this fits prior evidence This meta-analysis extends the evidence regarding GLP-1 receptor agonists in Type 2 Diabetes patients. It specifically addresses the impact on MACE and all-cause mortality, which aligns with previous findings that tirzepatide is associated with a significant reduction in MACE (OR 0.87) and all-cause mortality in T2DM patients. The finding of reduced heart failure hospitalization (HR 0.78) also relates to the known benefit of GLP-1 RA and SGLT2i combination therapy in heart failure.

Living with Type 2 Diabetes often comes with a heavy burden of worry regarding heart health. For many patients, the fear of heart failure or a major heart attack is a constant shadow. Because of these risks, finding treatments that can protect the heart while managing blood sugar is a major goal for doctors and patients alike. This is why researchers are looking closely at a class of medications known as GLP-1 receptor agonists.

To understand how these drugs work for the heart, researchers conducted a meta-analysis. This is a type of study that combines data from many different trials to see the bigger picture. They looked at data from a large group of 37,393 people who had Type 2 Diabetes and a history of heart issues. By looking at such a large number of people, the researchers hoped to see if these medications offered consistent benefits for heart health.

The results showed some encouraging trends. The study found that patients taking these medications had lower rates of all-cause mortality, which means fewer deaths from any cause. They also saw a lower rate of major adverse cardiovascular events, which is a term for serious heart problems like heart attacks. Additionally, there was a lower rate of heart failure or being hospitalized for heart failure. However, the results were not as clear for other specific issues. The study did not find a statistically significant difference for cardiovascular death, repeat heart attacks, or strokes.

While these findings are interesting, it is important to look at them with a balanced perspective. The researchers noted that the data had a lot of variety, which is called heterogeneity. This means the different studies they combined were not all very similar in how they were set up. Because of this variety, the results are considered exploratory. This means they are a good starting point for more research, but they do not provide a definitive answer just yet.

For patients today, this means that while these medications show potential for protecting the heart, they are not a guaranteed fix for everyone. Because the study was exploratory and had some limitations in how the data was grouped, these results should not be seen as a final word. If you have Type 2 Diabetes and concerns about your heart, the best step is to talk to your doctor about how these medications might fit into your specific health plan.

What this means for you:

GLP-1 medications show potential to lower heart failure risks in some patients with Type 2 Diabetes.

Study Details

Study typeMeta analysis

Sample sizen = 37,393

EvidenceLevel 1

PublishedSep 2026

PMID42387250

View Original Abstract ↓

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) who survive myocardial infarction (MI) remain at high risk for recurrent cardiovascular events and heart failure (HF). Although glucagon-like peptide-1 receptor agonist (GLP-1 RA) reduces cardiovascular events in stable atherosclerotic disease, its impact among patients with established MI has not been comprehensively synthesized. OBJECTIVES: To evaluate the association between GLP-1 RA use and cardiovascular outcomes in patients with T2DM across MI-defined cohorts. METHODS: We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Heterogeneity was evaluated using the I statistic, and 95% prediction intervals (PIs) were calculated to estimate the expected range of true effects in future clinical settings. Outcomes included all-cause mortality, cardiovascular death, study-defined major adverse cardiovascular events (MACE), MI, stroke, and HF or hospitalization for HF. A sensitivity analysis using the Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment was performed to account for the small number of included studies and substantial heterogeneity. Statistical analysis was performed using R software version 4.5.0. RESULTS: Seven studies, including 37,393 patients with T2DM from MI-defined populations (9556 receiving GLP-1 RA), were analyzed. GLP-1 RA use was associated with lower all-cause mortality (HR, 0.67; 95% CI, 0.49-0.90; I = 87.3%; PI, 0.27-1.63; P = 0.0085), reduced study-defined MACE (HR, 0.69; 95% CI, 0.56-0.84; I = 55.6%; PI, 0.44-1.06; P = 0.0002), and fewer HF events or hospitalizations for HF (HR, 0.78; 95% CI, 0.62-0.98; I = 77.6%; PI, 0.42-1.45; P = 0.0306). No significant associations were observed for cardiovascular death (HR, 0.85; 95% CI, 0.67-1.06; I = 0%; PI, 0.42-1.69; P = 0.15), recurrent MI (HR, 0.82; 95% CI, 0.62-1.09; I = 63%; PI, 0.41-1.63; P = 0.1753), or stroke (HR, 0.91; 95% CI, 0.68-1.22; I = 61.2%; PI, 0.40-2.05; P = 0.5237). In the sensitivity analysis using the HKSJ adjustment, statistical significance was lost for all endpoints, including all-cause mortality (P = 0.05), study-defined MACE (P = 0.13), and HF or hospitalization for HF (P = 0.06). CONCLUSIONS: In patients with T2DM across MI-defined populations, GLP-1 RA use showed signals toward lower all-cause mortality, study-defined MACE, and HF-related events; however, these findings remain exploratory because of substantial heterogeneity, wide PIs, and attenuation of statistical significance under HKSJ adjustment. REGISTRATION: PROSPERO identifier no. CRD420251270326.

GLP-1 receptor agonists reduce MACE (HR 0.69) and all-cause mortality (HR 0.67) in Type 2 DiabetesGLP-1 medications show promise for heart health in diabetes

How this fits prior evidence

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

GLP-1 receptor agonists reduce MACE (HR 0.69) and all-cause mortality (HR 0.67) in Type 2 DiabetesGLP-1 medications show promise for heart health in diabetes

How this fits prior evidence

More on Heart Failure

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties